A composite scaffold for treating infected bone defects and its preparation method
By combining a 3D-printed AgNPs/GO/nHA/PEGDA composite scaffold with M2 macrophage membrane vesicles, the challenge of bacterial eradication in infectious bone defects was solved, achieving multiple effects of antibacterial, immunomodulatory, and osteogenic effects, thus optimizing the treatment plan.
Patent Information
- Application Number
- CN202311372429.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-23
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-10-23
AI Technical Summary
Existing technologies are insufficient to effectively eradicate bacteria in infected bone defects. Long-term use of antibiotics can easily lead to drug-resistant bacteria, and revision surgery is difficult to thoroughly clean the wound, affecting the treatment outcome.
A composite scaffold of AgNPs/GO/nHA/PEGDA was fabricated using 3D printing technology. The scaffold was internally encapsulated with sodium alginate hydrogel to form M2 macrophage membrane vesicles, combining antibacterial and osteogenic properties to achieve sequential therapy.
This scaffold has antibacterial effects, avoids the side effects of antibiotics, regulates inflammatory responses, promotes bone tissue regeneration, and provides a more effective treatment strategy for infectious bone defects.
Abstract
Description
Technical Field
[0001] This invention relates to the field of bone scaffold technology, and more specifically, to a composite material scaffold for treating infected bone defects and a method for preparing the same. Background Technology
[0002] Bone infection is a recurrent, drug-resistant, and devastating disease that can lead to sepsis and even bone defects in severe cases. Currently, the most important principle in treating bone defects caused by infection is controlling the infection. Clinically, this usually involves long-term, large-scale use of antibiotics. When conditions permit, revision surgery can be performed to completely remove necrotic tissue and replace the implant with a new one. However, the success of revision surgery depends on thorough debridement, but it is difficult to eradicate bacteria that have been latent for a long time or have entered the bloodstream, and long-term antibiotic use increases the risk of developing drug-resistant bacteria. The refractory nature and high incidence of infected bone defects have spurred exploration and development in the field of biomaterials, with the search for novel implant materials becoming a research hotspot in recent years.
[0003] 3D printing technology can customize more precise implants according to clinical needs; however, simple biomaterials do not possess antibacterial properties, and the safety of biomaterials must also be considered. Therefore, this invention utilizes 3D printing technology to prepare a multi-effect integrated composite scaffold with antibacterial, immunomodulatory, and osteogenic functions. Its antibacterial, immunomodulatory, and osteogenic properties are verified in vivo and in vitro, providing a new strategy for the sequential treatment of infectious bone defects. Summary of the Invention
[0004] The purpose of this invention is to provide a composite scaffold for treating infected bone defects and its preparation method. The composite scaffold of AgNPs / GO / nHA / PEGDA is printed by photopolymerization using DLP. The printed scaffold contains sodium alginate hydrogel, and the hydrogel is filled with cell membrane vesicles derived from M2 macrophages, so as to achieve the purpose of sequential treatment of infected bone defects.
[0005] The above-mentioned technical objective of the present invention is achieved through the following technical solution: a composite material scaffold for treating infected bone defects and a method for preparing the same, comprising the following steps:
[0006] S1: Screening of suitable concentrations for the combined use of AgNps and GO; the optimal concentration ratio of 10:1 for the combined use of the two was screened through CCK8 and bacterial growth inhibition experiments.
[0007] S2: Preparation of photosensitive resin premix; The photosensitive resin premix consists of resin monomer PEG200DA, binder 3,3-dimethylacrylic acid and photoinitiator. nHA powder is mixed into the photosensitive resin premix in three batches to prepare photocurable slurry. Photocurable slurry with a solid phase ratio of 30wt% is prepared separately. After mixing, AgNps and GO are added at a mass ratio of 10:1 and placed on a vertical mixer and stirred for 4 hours.
[0008] S3: Pour the prepared photocurable slurry into the 3D printer hopper, and import the designed porous model into the ceramic printer. The model includes two specifications: φ5mm×h5mm and φ10mm×h2mm. The designed porosity is 75% and the pore diameter is 600μm. After setting the printing parameters, turn on the power and start printing. Clean the printed ceramic blank with high-pressure water jet.
[0009] S4: Preparation of cell membrane vesicles;
[0010] S5: Sodium alginate hydrogel is loaded with cell membrane vesicles and combined with a composite scaffold.
[0011] The present invention is further configured such that the preparation steps of the cell membrane vesicles are as follows:
[0012] A1: Prepare reagents: Melt and mix membrane protein extraction reagents A and B at room temperature, and place them on an ice bath immediately after melting; take an appropriate amount of membrane protein extraction reagents A and B for later use, and add PMSF a few minutes before use to make the final concentration of PMSF 1mM.
[0013] A2: Prepare cell or tissue samples; For adherent cells: Culture approximately 20-50 million cells, wash once with cold PBS, scrape off cells with a cell scraper or treat cells with cell digestion solution containing EDTA but without trypsin to loosen the cells from their adhesion, and pipette off the cells; collect cells by centrifugation, aspirate the supernatant, and keep the cell pellet for later use; gently resuspend the cell pellet with an appropriate amount of ice-cold PBS, take a small amount of cells for counting, and centrifuge the remaining cells at 4°C, 600g for 5 minutes to precipitate the cells; discard the supernatant, then centrifuge at 4°C, 600g for 1 minute to precipitate the residual liquid on the centrifuge tube wall and further precipitate the cells, aspirate the residual liquid; add 1 ml of membrane protein extraction reagent A with added PMSF to the 20-50 million cells, gently and thoroughly suspend the cells, and incubate on ice for 10-15 minutes;
[0014] A3: Disruption of cell or tissue samples and identification of disruption effect: Use an ultrasonic probe until the cell suspension is clear, power 25%, sonicate for 5 seconds, stop for 3 seconds, until clear and bright;
[0015] A4: Remove cell nuclei and unbroken cells: Centrifuge at 4000g for 20 minutes at 4℃, collect the supernatant into a new centrifuge tube; leave 30-50 μL of supernatant residue without aspirating to ensure that the aspirated supernatant has high purity;
[0016] A5: Precipitate cell membrane debris: Centrifuge at 16000g for 45 minutes at 4℃ to precipitate cell membrane debris;
[0017] A6: Cell membrane vesicles with a particle size of 200 nm were prepared using a liposome extruder.
[0018] The present invention is further configured such that the step S5, in which sodium alginate hydrogel is loaded with cell membrane vesicles and combined with the composite scaffold, is as follows:
[0019] ① Sodium alginate powder was dissolved in double-distilled water and stirred thoroughly until dissolved. The resulting cell membrane vesicle solution was then mixed with the dissolved sodium alginate powder to prepare a 2% sodium alginate mixed solution.
[0020] ② Dissolve CaCl2 powder in double-distilled water to prepare a 1% aqueous solution for later use;
[0021] ③ Immerse the printed composite scaffold in sodium alginate aqueous solution and place it on a magnetic stirrer for continuous stirring. Add CaCl2 solution dropwise at a uniform rate to crosslink. After crosslinking is completed, remove the scaffold and immerse it in a new CaCl2 solution overnight to allow it to fully crosslink.
[0022] ④ Remove the hydrogel on the surface of the scaffold, leaving only the hydrogel inside the scaffold.
[0023] In summary, the present invention has the following beneficial effects: (1) The stent has antibacterial effect, avoiding the side effects of long-term use of antibiotics. In addition, AgNps is also effective against drug-resistant bacteria, solving the problem that long-term use of antibiotics easily leads to the generation of drug-resistant bacteria.
[0024] (2) Infection can trigger an inflammatory response, and long-term inflammatory response can affect tissue regeneration. The M2 macrophage vesicles in this scaffold can effectively regulate the inflammatory response and create a suitable environment for tissue regeneration.
[0025] (3) GO and nHA in the scaffold can exert a synergistic osteogenic effect, ultimately promoting bone tissue regeneration.
[0026] In summary, this scaffold has multiple effects including antibacterial, immunomodulatory, and osteogenic properties, avoiding the side effects of antibiotics and the risk of secondary bone grafting for patients. It optimizes current treatment options and provides a new strategy for the sequential treatment of infected bone defects. Detailed Implementation
[0027] The present invention will be further described in detail below with reference to the embodiments.
[0028] Example: A composite scaffold for treating infected bone defects and its preparation method, for achieving sequential treatment of infected bone defects. This technical solution includes: photopolymerization printing of an AgNPs / GO / nHA / PEGDA composite scaffold using DLP (Digital Laser Processing), wherein the printed scaffold contains sodium alginate hydrogel, and the hydrogel encapsulates cell membrane vesicles derived from M2 macrophages.
[0029] The fabrication of the composite scaffold includes the following steps:
[0030] The optimal concentration for the combined use of AgNps and GO was screened; the optimal concentration for their combined use was determined through CCK8 assay and bacterial growth inhibition assay. The final determined ratio for their combined use was 10:1.
[0031] Fabrication of composite scaffolds:
[0032] (1) First, a photosensitive resin premix was prepared. The photosensitive resin premix consisted of resin monomer PEG200DA, binder 3,3-dimethylacrylic acid, and photoinitiator. nHA powder was mixed into the photosensitive resin premix in three batches to obtain a photocurable slurry. Photocurable slurries with a solid phase ratio of 30wt% were prepared separately. After mixing, AgNps and GO were added at a mass ratio of 10:1 and placed on a vertical mixer and stirred for 4 hours.
[0033] (2) Pour the prepared photocurable slurry into the printer's feed tank, and import the designed porous model into the ceramic printer. The model includes two specifications: φ5mm×h5mm and φ10mm×h2mm, with a designed porosity of 75% and a pore size of 600μm. After setting the printing parameters, turn on the power and start printing. Clean the printed ceramic blank with high-pressure water jet. Preparation of composite hydrogel.
[0034] 1. Preparation of cell membrane vesicles
[0035] ①Prepare reagents: Melt and mix membrane protein extraction reagents A and B at room temperature, and immediately place on an ice bath after melting. Take an appropriate amount of membrane protein extraction reagents A and B for later use. Add PMSF a few minutes before use to make the final concentration of PMSF 1mM.
[0036] ②Prepare cell or tissue samples:
[0037] (1) Collecting cells
[0038] For adherent cells: Culture approximately 20-50 million cells, wash once with cold PBS, scrape the cells off with a cell scraper or treat the cells with a cell digestion solution containing EDTA but without trypsin to loosen the cells from adhesion, and then pipette the cells off. Centrifuge to collect the cells, aspirate the supernatant, and keep the cell pellet for later use. Avoid using trypsin to digest the cells as much as possible, as trypsin may degrade the target membrane proteins to be extracted.
[0039] (2) Washing cells: Gently resuspend the cell pellet with an appropriate amount of ice-cold PBS. Take a small number of cells for counting. Centrifuge the remaining cells at 4°C and 600g for 5 minutes to precipitate the cells. Discard the supernatant, and then centrifuge at 4°C and 600g for 1 minute to precipitate the residual liquid on the centrifuge tube wall and further precipitate the cells. Make every effort to remove the residual liquid.
[0040] (3) Cell pretreatment: Add 1 ml of membrane protein extraction reagent A with added PMSF to 20-50 million cells, gently and fully suspend the cells, and place them in an ice bath for 10-15 minutes.
[0041] ③ Disruption of cell or tissue samples and identification of disruption effect: Use the probe to sonicate until the cell suspension is clear, power 25%, sonicate for 5 seconds, stop for 3 seconds, until clear.
[0042] ④ Remove cell nuclei and unbroken cells: Centrifuge at 4000g for 20 minutes at 4℃, and carefully collect the supernatant into a new centrifuge tube. Do not touch the precipitate when aspirating the supernatant! Approximately 30-50 μL of supernatant may remain and not aspirate to ensure high purity of the aspirated supernatant.
[0043] ⑤ Precipitate cell membrane fragments: Centrifuge at 16000g for 45 minutes at 4℃ to precipitate cell membrane fragments and obtain the cell membrane.
[0044] ⑥ Cell membrane vesicles with a particle size of approximately 200 nm were prepared using a liposome extruder.
[0045] 2. Sodium alginate hydrogel carries cell membrane vesicles and binds to a composite scaffold.
[0046] ① Sodium alginate powder was dissolved in double-distilled water and stirred thoroughly until dissolved. The resulting cell membrane vesicle solution was then mixed with the dissolved sodium alginate powder to prepare a 2% sodium alginate mixed solution.
[0047] ② Dissolve CaCl2 powder in double-distilled water to prepare a 1% aqueous solution for later use.
[0048] ③ Immerse the printed composite scaffold in sodium alginate aqueous solution and place it on a magnetic stirrer for continuous stirring. Add CaCl2 solution dropwise at a uniform rate to crosslink. After crosslinking is complete, remove the scaffold and immerse it in a fresh CaCl2 solution overnight to allow it to fully crosslink.
[0049] ④ Remove the hydrogel on the surface of the scaffold, leaving only the hydrogel inside the scaffold.
[0050] Compared with existing treatments for infected bone defects, this invention provides a composite scaffold for sequential treatment of infected bone defects, which has the following beneficial effects:
[0051] This stent has antibacterial effects, avoiding the side effects of long-term antibiotic use. In addition, AgNps is also effective against drug-resistant bacteria, solving the problem that long-term antibiotic use easily leads to drug-resistant bacteria.
[0052] Infections can trigger inflammatory responses, and long-term inflammation can affect tissue regeneration. The M2 macrophage vesicles in this scaffold can effectively regulate inflammatory responses and create a suitable environment for tissue regeneration.
[0053] GO and nHA in the scaffold can exert a synergistic osteogenic effect, ultimately promoting bone tissue regeneration.
[0054] This specific embodiment is merely an explanation of the present invention and is not intended to limit the invention. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they are within the scope of the claims of the present invention.
Claims
1. A method for preparing a composite material scaffold for treating infected bone defects, characterized in that, The process includes the following steps: S1: Screening of suitable concentrations for the combined use of AgNps and GO; the optimal concentration ratio of 10:1 for the combined use of the two was screened through CCK8 and bacterial growth inhibition experiments. S2: Preparation of photosensitive resin premix; The photosensitive resin premix consists of resin monomer PEG200DA, binder 3,3-dimethylacrylic acid and photoinitiator. nHA powder is mixed into the photosensitive resin premix in three batches to prepare photocurable slurry. Photocurable slurry with a solid phase ratio of 30wt% is prepared separately. After mixing, AgNps and GO are added at a mass ratio of 10:1 and the mixture is stirred on a vertical mixer for 4 hours. S3: Pour the prepared photocurable slurry into the 3D printer's material tank, and import the designed porous model into the ceramic printer. The model includes two specifications: φ5mm×h5mm and φ10mm×h2mm. The designed porosity is 75% and the pore diameter is 600μm. After setting the printing parameters, turn on the power and start printing. Clean the printed ceramic blank with high-pressure water jet. S4: Preparation of cell membrane vesicles; The preparation steps of the cell membrane vesicles are as follows: A1: Prepare reagents: Melt and mix membrane protein extraction reagents A and B at room temperature, and place them on an ice bath immediately after melting; take an appropriate amount of membrane protein extraction reagents A and B for later use, and add PMSF a few minutes before use to make the final concentration of PMSF 1mM. A2: Prepare cell or tissue samples; For adherent cells: Culture 20-50 million cells, wash once with cold PBS, scrape off cells with a cell scraper or treat cells with cell digestion solution containing EDTA but without trypsin to loosen the cells from the wall, and pipette off the cells; collect cells by centrifugation, aspirate the supernatant, and keep the cell pellet for later use; resuspend the cell pellet with an appropriate amount of ice-cold PBS, take a small amount of cells for counting, and centrifuge the remaining cells at 4°C, 600g for 5 minutes to precipitate the cells; discard the supernatant, then centrifuge at 4°C, 600g for 1 minute to precipitate the residual liquid on the centrifuge tube wall and precipitate the cells, and aspirate the residual liquid; add 1 ml of membrane protein extraction reagent A with added PMSF to the 20-50 million cells, and fully suspend the cells, and incubate on ice for 10-15 minutes; A3: Disruption of cell or tissue samples and identification of disruption effect: Use an ultrasonic probe until the cell suspension is clear, power 25%, sonicate for 5 seconds, stop for 3 seconds, until clear and bright; A4: Remove cell nuclei and unbroken cells: Centrifuge at 4000g for 20 minutes at 4℃, collect the supernatant into a new centrifuge tube; leave 30-50 μL of supernatant residue without aspirating to ensure that the aspirated supernatant has high purity; A5: Precipitate cell membrane debris: Centrifuge at 16000g for 45 minutes at 4℃ to precipitate cell membrane debris; A6: Cell membrane vesicles with a particle size of 200 nm were prepared using a liposome extruder; S5: Sodium alginate hydrogel is loaded with cell membrane vesicles and combined with a composite scaffold; The steps in S5, which involve attaching sodium alginate hydrogel to cell membrane vesicles and combining it with the composite scaffold, are as follows: ① Sodium alginate powder was dissolved in double-distilled water and stirred thoroughly until dissolved. The prepared cell membrane vesicle solution was then mixed with the dissolved sodium alginate powder to prepare a 2% sodium alginate mixed solution. ② Dissolve CaCl2 powder in double-distilled water to prepare a 1% aqueous solution for later use; ③ Immerse the printed composite scaffold in sodium alginate aqueous solution and place it on a magnetic stirrer for continuous stirring. Add CaCl2 solution dropwise at a uniform rate to crosslink. After crosslinking is completed, remove the scaffold and immerse it in a new CaCl2 solution overnight to allow it to fully crosslink. ④ Remove the hydrogel on the surface of the scaffold, leaving only the hydrogel inside the scaffold.
Citation Information
Patent Citations
Systems and methods for multi-analysis
CN103946364A
Resurrection Of Antibiotics That MRSA Resists By Silver-Doped Bioactive Glass-Ceramic Particles
US20210402062A1
